Loading...
•
Nov 30, 2025
AngioDynamics Q2 2026 Earnings Report
Estimated Revenue:$77M
+7.0% YoY
Estimated EPS:-$0.1
+10.1% YoY
Key Takeaways
AngioDynamics delivered solid Q2 results, supported by strong Med Tech segment growth and positive adjusted EBITDA. The company raised guidance for full-year net sales and adjusted EBITDA.
Revenue reached $79,433,000, up from $73,015,000 in the prior-year period.
Adjusted EPS was breakeven at $0.00, while GAAP EPS showed a net loss of $0.15.
Med Tech segment grew to $35,653,000 driven by strength in Auryon, AlphaVac, and NanoKnife.
Adjusted EBITDA increased to $5,937,000, reflecting disciplined execution and improved gross margin.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
AngioDynamics raised its FY2026 guidance for both net sales and adjusted EBITDA, expecting continued Med Tech growth and positive cash flow.
Positive Outlook
- FY26 net sales guidance raised to $312M–$314M
- Adjusted EBITDA guidance increased to $8M–$10M
- Continued double-digit Med Tech segment growth expected
- Expecting positive cash flow for full year FY26
- Received multiple FDA approvals to support product portfolio expansion
Challenges Ahead
- Tariff impact estimated at $4M–$6M for FY26
- GAAP net loss continued in Q2
- Adjusted EPS guidance remains in negative territory: ($0.33) – ($0.23)
- Challenges in global macro environment may impact growth
- Ongoing need to offset Med Device flat-to-low growth with Med Tech gains
Loading...
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...